Raimund J. Ober
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Raimund J. Ober has a total of 196 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Sally Ward
Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, Texas, USA
116 shared publications Sripad Ram
Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, TX 77843, USA
37 shared publicationsJerry Chao
ADepartment of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA
28 shared publicationsZhiping Lin
School of Electrical and Electronic Engineering, Nanyang Technological University, Singapore
11 shared publicationsPrashant Prabhat
Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, 75390
10 shared publicationsRamraj Velmurugan
Department of Molecular and Cellular Medicine, Texas A&M University Health Science Center, College Station, TX, USA
9 shared publications
Latest Publications
- Open Access
Fisher information matrix for single molecules with stochastic trajectories
Tracking of objects in cellular environments has become a vital tool in molecular cell biology. A particularly important example is single molecule tracking which enables the study of the motion of a molecule in cellular environments and provides quantitative information on the behavior of individual molecules in cellular environments, which were not available before through bulk studies. Here, we consider a dynamical system where the motion of an object is modeled by stochastic differential equations (SDEs), and measurements are the detected photons emitted by the moving fluorescently labeled object, which occur at discrete time points, corresponding to the arrival times of a Poisson process, in contrast to uniform time points which have been commonly used in similar dynamical systems. The measurements are distributed according to optical diffraction theory, and therefore, they would be modeled by different distributions, e.g., a Born and Wolf profile for an out-of-focus molecule. For some special circumstances, Gaussian image models have been proposed. In this paper, we introduce a stochastic framework in which we calculate the maximum likelihood estimates of the biophysical parameters of the molecular interactions, e.g., diffusion and drift coefficients. More importantly, we develop a general framework to calculate the Cram\'er-Rao lower bound (CRLB), given by the inverse of the Fisher information matrix, for the estimation of unknown parameters and use it as a benchmark in the evaluation of the standard deviation of the estimates. There exists no established method, even for Gaussian measurements, to systematically calculate the CRLB for the general motion model that we consider in this paper. We apply the developed methodology to simulated data of a molecule with linear trajectories and show that the standard deviation of the estimates matches well with the square root of the CRLB.
Open AccessFisher information matrix for single molecules with stochastic trajectories
Tracking of objects in cellular environments has become a vital tool in molecular cell biology. A particularly important example is single molecule tracking which enables the study of the motion of a molecule in cellular environments and provides quantitative information on the behavior of individual molecules in cellular environments, which were not available before through bulk studies. Here, we consider a dynamical system where the motion of an object is modeled by stochastic differential equations (SDEs), and measurements are the detected photons emitted by the moving fluorescently labeled object, which occur at discrete time points, corresponding to the arrival times of a Poisson process, in contrast to uniform time points which have been commonly used in similar dynamical systems. The measurements are distributed according to optical diffraction theory, and therefore, they would be modeled by different distributions, e.g., a Born and Wolf profile for an out-of-focus molecule. For some special circumstances, Gaussian image models have been proposed. In this paper, we introduce a stochastic framework in which we calculate the maximum likelihood estimates of the biophysical parameters of the molecular interactions, e.g., diffusion and drift coefficients. More importantly, we develop a general framework to calculate the Cram\'er-Rao lower bound (CRLB), given by the inverse of the Fisher information matrix, for the estimation of unknown parameters and use it as a benchmark in the evaluation of the standard deviation of the estimates. There exists no established method, even for Gaussian measurements, to systematically calculate the CRLB for the general motion model that we consider in this paper. We apply the developed methodology to simulated data of a molecule with linear trajectories and show that the standard deviation of the estimates matches well with the square root of the CRLB.
- Open Access
- 30 April 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (5) , 848-860
Neonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis
The maintenance of the homeostasis of immunoglobulin G (IgG) represents a fundamental aspect of humoral immunity that has direct relevance to the successful delivery of antibody-based therapeutics. The ubiquitously expressed neonatal Fc receptor (FcRn) salvages IgG from cellular degradation following pinocytic uptake into cells, conferring prolonged in vivo persistence on IgG. However, the cellular sites of FcRn function are poorly defined. Pinocytic uptake is a prerequisite for FcRn-mediated IgG salvage, prompting us to investigate the consequences of IgG uptake and catabolism by macrophages, which represent both abundant and highly pinocytic cells in the body. Site-specific deletion of FcRn to generate mice harboring FcRn-deficient macrophages results in IgG hypercatabolism and ~threefold reductions in serum IgG levels, whereas these effects were not observed in mice that lack functional FcRn in B cells and dendritic cells. Consistent with the degradative activity of FcRn-deficient macrophages, depletion of these cells in FcRn-deficient mice leads to increased persistence and serum levels of IgG. These studies demonstrate a pivotal role for FcRn-mediated salvage in compensating for the high pinocytic and degradative activities of macrophages to maintain IgG homeostasis.
- 30 April 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (5) , 848-860
Open AccessNeonatal Fc receptor expression in macrophages is indispensable for IgG homeostasis
The maintenance of the homeostasis of immunoglobulin G (IgG) represents a fundamental aspect of humoral immunity that has direct relevance to the successful delivery of antibody-based therapeutics. The ubiquitously expressed neonatal Fc receptor (FcRn) salvages IgG from cellular degradation following pinocytic uptake into cells, conferring prolonged in vivo persistence on IgG. However, the cellular sites of FcRn function are poorly defined. Pinocytic uptake is a prerequisite for FcRn-mediated IgG salvage, prompting us to investigate the consequences of IgG uptake and catabolism by macrophages, which represent both abundant and highly pinocytic cells in the body. Site-specific deletion of FcRn to generate mice harboring FcRn-deficient macrophages results in IgG hypercatabolism and ~threefold reductions in serum IgG levels, whereas these effects were not observed in mice that lack functional FcRn in B cells and dendritic cells. Consistent with the degradative activity of FcRn-deficient macrophages, depletion of these cells in FcRn-deficient mice leads to increased persistence and serum levels of IgG. These studies demonstrate a pivotal role for FcRn-mediated salvage in compensating for the high pinocytic and degradative activities of macrophages to maintain IgG homeostasis.
- Top Cited Papers
- 8 April 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (5) , 387-395
Super-resolution fight club: assessment of 2D and 3D single-molecule localization microscopy software
With the widespread uptake of two-dimensional (2D) and three-dimensional (3D) single-molecule localization microscopy (SMLM), a large set of different data analysis packages have been developed to generate super-resolution images. In a large community effort, we designed a competition to extensively characterize and rank the performance of 2D and 3D SMLM software packages. We generated realistic simulated datasets for popular imaging modalities—2D, astigmatic 3D, biplane 3D and double-helix 3D—and evaluated 36 participant packages against these data. This provides the first broad assessment of 3D SMLM software and provides a holistic view of how the latest 2D and 3D SMLM packages perform in realistic conditions. This resource allows researchers to identify optimal analytical software for their experiments, allows 3D SMLM software developers to benchmark new software against the current state of the art, and provides insight into the current limits of the field.
- 8 April 2019
- Published by Springer Nature in Nature Methods
- Vol. 16 (5) , 387-395
Top Cited PapersSuper-resolution fight club: assessment of 2D and 3D single-molecule localization microscopy software
With the widespread uptake of two-dimensional (2D) and three-dimensional (3D) single-molecule localization microscopy (SMLM), a large set of different data analysis packages have been developed to generate super-resolution images. In a large community effort, we designed a competition to extensively characterize and rank the performance of 2D and 3D SMLM software packages. We generated realistic simulated datasets for popular imaging modalities—2D, astigmatic 3D, biplane 3D and double-helix 3D—and evaluated 36 participant packages against these data. This provides the first broad assessment of 3D SMLM software and provides a holistic view of how the latest 2D and 3D SMLM packages perform in realistic conditions. This resource allows researchers to identify optimal analytical software for their experiments, allows 3D SMLM software developers to benchmark new software against the current state of the art, and provides insight into the current limits of the field.
- 1 April 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (5) , 523-526
Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
- 1 April 2019
- Published by Springer Nature in Nature Biotechnology
- Vol. 37 (5) , 523-526
Engineering a HER2-specific antibody–drug conjugate to increase lysosomal delivery and therapeutic efficacy
- Open Access
- 15 February 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-12
Resolution limit of image analysis algorithms
The resolution of an imaging system is a key property that, despite many advances in optical imaging methods, remains difficult to define and apply. Rayleigh’s and Abbe’s resolution criteria were developed for observations with the human eye. However, modern imaging data is typically acquired on highly sensitive cameras and often requires complex image processing algorithms to analyze. Currently, no approaches are available for evaluating the resolving capability of such image processing algorithms that are now central to the analysis of imaging data, particularly location-based imaging data. Using methods of spatial statistics, we develop a novel algorithmic resolution limit to evaluate the resolving capabilities of location-based image processing algorithms. We show how insufficient algorithmic resolution can impact the outcome of location-based image analysis and present an approach to account for algorithmic resolution in the analysis of spatial location patterns.
- 15 February 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-12
Open AccessResolution limit of image analysis algorithms
The resolution of an imaging system is a key property that, despite many advances in optical imaging methods, remains difficult to define and apply. Rayleigh’s and Abbe’s resolution criteria were developed for observations with the human eye. However, modern imaging data is typically acquired on highly sensitive cameras and often requires complex image processing algorithms to analyze. Currently, no approaches are available for evaluating the resolving capability of such image processing algorithms that are now central to the analysis of imaging data, particularly location-based imaging data. Using methods of spatial statistics, we develop a novel algorithmic resolution limit to evaluate the resolving capabilities of location-based image processing algorithms. We show how insufficient algorithmic resolution can impact the outcome of location-based image analysis and present an approach to account for algorithmic resolution in the analysis of spatial location patterns.
- 1 October 2018
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 39 (10) , 892-904
Targeting FcRn to Generate Antibody-Based Therapeutics
- 1 October 2018
- Published by Elsevier in Trends in Pharmacological Sciences
- Vol. 39 (10) , 892-904
Targeting FcRn to Generate Antibody-Based Therapeutics
- Top Cited PapersOpen Access
- 24 July 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (10) , 4372-4386
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
BACKGROUND. Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs. METHODS. A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The findings of this study were compared with the pharmacodynamics profile elicited by efgartigimod in cynomolgus monkeys. RESULTS. Efgartigimod treatment resulted in a rapid and specific clearance of serum IgG levels in both cynomolgus monkeys and healthy volunteers. In humans, single administration of efgartigimod reduced IgG levels up to 50%, while multiple dosing further lowered IgGs on average by 75% of baseline levels. Approximately 8 weeks following the last administration, IgG levels returned to baseline. Efgartigimod did not alter the homeostasis of albumin or Igs other than IgG, and no serious adverse events related to efgartigimod infusion were observed. CONCLUSION. Antagonizing FcRn using efgartigimod is safe and results in a specific, profound, and sustained reduction of serum IgG levels. These results warrant further evaluation of this therapeutic approach in IgG-driven autoimmune diseases. TRIAL REGISTRATION. Clinicaltrials.gov NCT03457649. FUNDING. argenx BVBA.
- 24 July 2018
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (10) , 4372-4386
Top Cited PapersOpen AccessNeonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
BACKGROUND. Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating IgG levels can, however, be associated with some severe adverse reactions and a substantial burden to patients. Targeting the neonatal Fc receptor (FcRn) presents an innovative and potentially more effective, safer, and more convenient alternative for clearing pathogenic IgGs. METHODS. A randomized, double-blind, placebo-controlled first-in-human study was conducted in 62 healthy volunteers to explore single and multiple ascending intravenous doses of the FcRn antagonist efgartigimod. The study objectives were to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. The findings of this study were compared with the pharmacodynamics profile elicited by efgartigimod in cynomolgus monkeys. RESULTS. Efgartigimod treatment resulted in a rapid and specific clearance of serum IgG levels in both cynomolgus monkeys and healthy volunteers. In humans, single administration of efgartigimod reduced IgG levels up to 50%, while multiple dosing further lowered IgGs on average by 75% of baseline levels. Approximately 8 weeks following the last administration, IgG levels returned to baseline. Efgartigimod did not alter the homeostasis of albumin or Igs other than IgG, and no serious adverse events related to efgartigimod infusion were observed. CONCLUSION. Antagonizing FcRn using efgartigimod is safe and results in a specific, profound, and sustained reduction of serum IgG levels. These results warrant further evaluation of this therapeutic approach in IgG-driven autoimmune diseases. TRIAL REGISTRATION. Clinicaltrials.gov NCT03457649. FUNDING. argenx BVBA.
- Open Access
Phagocytosis of antibody‐opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages
Despite the rapidly expanding use of antibody‐based therapeutics to treat cancer, knowledge of the cellular processes following phagocytosis of antibody‐opsonized tumor cells is limited. Here we report the formation of a phagosome‐associated vacuole that is observed in macrophages as these degradative compartments mature following phagocytosis of HER2‐positive cancer cells in the presence of the HER2‐specific antibody, trastuzumab. We demonstrate that this vacuole is a distinct organelle that is closely apposed to the phagosome. Furthermore, the size of the phagosome‐associated vacuole is increased by inhibition of the mTOR pathway. Collectively, the identification of this vacuolar compartment has implications for understanding the subcellular trafficking processes leading to the destruction of phagocytosed, antibody‐opsonized cancer cells by macrophages.
Open AccessPhagocytosis of antibody‐opsonized tumor cells leads to the formation of a discrete vacuolar compartment in macrophages
Despite the rapidly expanding use of antibody‐based therapeutics to treat cancer, knowledge of the cellular processes following phagocytosis of antibody‐opsonized tumor cells is limited. Here we report the formation of a phagosome‐associated vacuole that is observed in macrophages as these degradative compartments mature following phagocytosis of HER2‐positive cancer cells in the presence of the HER2‐specific antibody, trastuzumab. We demonstrate that this vacuole is a distinct organelle that is closely apposed to the phagosome. Furthermore, the size of the phagosome‐associated vacuole is increased by inhibition of the mTOR pathway. Collectively, the identification of this vacuolar compartment has implications for understanding the subcellular trafficking processes leading to the destruction of phagocytosed, antibody‐opsonized cancer cells by macrophages.
- Open Access
- 1 January 2018
- Published by Elsevier in Journal of Autoimmunity
- Vol. 86, 104-115
Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model
- 1 January 2018
- Published by Elsevier in Journal of Autoimmunity
- Vol. 86, 104-115
Open AccessMyelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis patients exacerbate disease in a humanized mouse model
- 1 January 2018
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 17 (1) , 169-182
Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer
In response to cellular stress, phosphatidylserine is exposed on the outer membrane leaflet of tumor blood vessels and cancer cells, motivating the development of phosphatidylserine-specific therapies. The generation of drug-conjugated phosphatidylserine-targeting agents represents an unexplored therapeutic approach, for which antitumor effects are critically dependent on efficient internalization and lysosomal delivery of the cytotoxic drug. In the current study, we have generated phosphatidylserine-targeting agents by fusing phosphatidylserine-binding domains to a human IgG1-derived Fc fragment. The tumor localization and pharmacokinetics of several phosphatidylserine-specific Fc fusions have been analyzed in mice and demonstrate that Fc-Syt1, a fusion containing the synaptotagmin 1 C2A domain, effectively targets tumor tissue. Conjugation of Fc-Syt1 to the cytotoxic drug monomethyl auristatin E results in a protein–drug conjugate (PDC) that is internalized into target cells and, due to the Ca2+ dependence of phosphatidylserine binding, dissociates from phosphatidylserine in early endosomes. The released PDC is efficiently delivered to lysosomes and has potent antitumor effects in mouse xenograft tumor models. Interestingly, although an engineered, tetravalent Fc-Syt1 fusion shows increased binding to target cells, this higher avidity variant demonstrates reduced persistence and therapeutic effects compared with bivalent Fc-Syt1. Collectively, these studies show that finely tuned, Ca2+-switched phosphatidylserine-targeting agents can be therapeutically efficacious. Mol Cancer Ther; 17(1); 169–82. ©2017 AACR.
- 1 January 2018
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 17 (1) , 169-182
Targeting Phosphatidylserine with Calcium-Dependent Protein–Drug Conjugates for the Treatment of Cancer
In response to cellular stress, phosphatidylserine is exposed on the outer membrane leaflet of tumor blood vessels and cancer cells, motivating the development of phosphatidylserine-specific therapies. The generation of drug-conjugated phosphatidylserine-targeting agents represents an unexplored therapeutic approach, for which antitumor effects are critically dependent on efficient internalization and lysosomal delivery of the cytotoxic drug. In the current study, we have generated phosphatidylserine-targeting agents by fusing phosphatidylserine-binding domains to a human IgG1-derived Fc fragment. The tumor localization and pharmacokinetics of several phosphatidylserine-specific Fc fusions have been analyzed in mice and demonstrate that Fc-Syt1, a fusion containing the synaptotagmin 1 C2A domain, effectively targets tumor tissue. Conjugation of Fc-Syt1 to the cytotoxic drug monomethyl auristatin E results in a protein–drug conjugate (PDC) that is internalized into target cells and, due to the Ca2+ dependence of phosphatidylserine binding, dissociates from phosphatidylserine in early endosomes. The released PDC is efficiently delivered to lysosomes and has potent antitumor effects in mouse xenograft tumor models. Interestingly, although an engineered, tetravalent Fc-Syt1 fusion shows increased binding to target cells, this higher avidity variant demonstrates reduced persistence and therapeutic effects compared with bivalent Fc-Syt1. Collectively, these studies show that finely tuned, Ca2+-switched phosphatidylserine-targeting agents can be therapeutically efficacious. Mol Cancer Ther; 17(1); 169–82. ©2017 AACR.